{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T03:49:02Z","timestamp":1792986542614,"version":"4.5.0"},"reference-count":47,"publisher":"Akademiai Kiado Zrt.","issue":"18","license":[{"start":{"date-parts":[[2024,5,5]],"date-time":"2024-05-05T00:00:00Z","timestamp":1714867200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.akjournals.com"],"crossmark-restriction":true},"short-container-title":["OH"],"published-print":{"date-parts":[[2024,5,5]]},"abstract":"<jats:p>\n                    <jats:italic>Bevezet\u00e9s:<\/jats:italic>\n                    Az ESC 2021-es Sz\u00edvel\u00e9gtelens\u00e9g Ir\u00e1nyelve egy\u00e9rtelm\u0171\n                    \u00fatmutat\u00e1st ad a cs\u00f6kkent ejekci\u00f3s frakci\u00f3j\u00fa sz\u00edvel\u00e9gtelens\u00e9g gy\u00f3gyszeres\n                    kezel\u00e9s\u00e9re. A konvencion\u00e1lis neurohormon\u00e1lis antagonista h\u00e1rmas ter\u00e1pia (TT)\n                    (RASi + \u03b2B + MRA) a leg\u00fajabb vizsg\u00e1latok eredm\u00e9nyei alapj\u00e1n a minden beteg\n                    sz\u00e1m\u00e1ra javasolt k\u00e9sz\u00edtm\u00e9nyeket illet\u0151en az SGLT2i-kkel eg\u00e9sz\u00fclt ki.\n                    <jats:italic>C\u00e9lkit\u0171z\u00e9s:<\/jats:italic>\n                    C\u00e9lunk volt annak felm\u00e9r\u00e9se a 2021-es\n                    Sz\u00edvel\u00e9gtelens\u00e9g Ir\u00e1nyelv t\u00fckr\u00e9ben, hogy a cs\u00f6kkent ejekci\u00f3s frakci\u00f3j\u00fa\n                    sz\u00edvel\u00e9gtelens\u00e9g gy\u00f3gyszeres kezel\u00e9s\u00e9ben milyen az els\u0151 vonalbeli n\u00e9gyes ter\u00e1pia\n                    (QT) (RASi + \u03b2B + MRA + SGLT2i) alkalmaz\u00e1si ar\u00e1nya, \u00e9s a ter\u00e1pia milyen hat\u00e1st\n                    gyakorol a progn\u00f3zisra.\n                    <jats:italic>M\u00f3dszer:<\/jats:italic>\n                    Int\u00e9zet\u00fcnk Sz\u00edvel\u00e9gtelens\u00e9g\n                    R\u00e9szleg\u00e9n 2021. 04. 01. \u00e9s 2023. 12. 31. k\u00f6z\u00f6tt sz\u00edvel\u00e9gtelens\u00e9g miatt\n                    hospitaliz\u00e1lt, konszekut\u00edv cs\u00f6kkent ejekci\u00f3s frakci\u00f3j\u00fa sz\u00edvel\u00e9gtelens\u00e9gben\n                    szenved\u0151 betegcsoport retrospekt\u00edv adatelemz\u00e9s\u00e9t v\u00e9gezt\u00fck. A betegeket a 2021-es\n                    Sz\u00edvel\u00e9gtelens\u00e9gi Ir\u00e1nyelv publik\u00e1l\u00e1sa el\u0151tt, illetve azt k\u00f6vet\u0151en hospitaliz\u00e1lt\n                    csoportba soroltuk. A gy\u00f3gyszeres ter\u00e1pia alkalmaz\u00e1sa k\u00f6z\u00f6tti k\u00fcl\u00f6nbs\u00e9geket\n                    Fisher-teszttel elemezt\u00fck. Az 1 \u00e9ves hal\u00e1loz\u00e1st Kaplan\u2013Meier-f\u00e9le anal\u00edzissel \u00e9s\n                    log-rank teszttel hasonl\u00edtottuk \u00f6ssze.\n                    <jats:italic>Eredm\u00e9nyek:<\/jats:italic>\n                    A 346 f\u0151s\n                    kohorsz (f\u00e9rfi: 76%, kor: 61 [50\u201370] \u00e9v, koszor\u00fa\u00e9r-betegs\u00e9g: 46%, diabetes: 36%,\n                    pitvarfibrill\u00e1ci\u00f3\/flutter: 42%, LVEF: 25 [20\u201330]%, becs\u00fclt glomerularis\n                    filtr\u00e1ci\u00f3s r\u00e1ta: 57 [45\u201373] ml\/min\/1,73 m\n                    <jats:sup>2<\/jats:sup>\n                    ; NT-proBNP: 4848\n                    [2389\u20139307] pg\/ml) nagy ar\u00e1nyban r\u00e9szes\u00fclt TT-ben (83%) \u00e9s QT-ben (51%)\n                    elbocs\u00e1t\u00e1skor. Az ESC 2021-es Sz\u00edvel\u00e9gtelens\u00e9g Ir\u00e1nyelv\u00e9nek publik\u00e1l\u00e1s\u00e1t\n                    k\u00f6vet\u0151en az SGLT2i-k alkalmaz\u00e1sa szignifik\u00e1nsan javult (19%\n                    <jats:italic>vs.<\/jats:italic>\n                    60%, p&lt;0,001; az Ir\u00e1nyelv publik\u00e1l\u00e1sa el\u0151tt\n                    <jats:italic>vs.<\/jats:italic>\n                    ut\u00e1n\n                    hospitaliz\u00e1lt csoportban), \u00edgy a QT-n l\u00e9v\u0151k ar\u00e1nya is jelent\u0151sen emelkedett (19%\n                    <jats:italic>vs.<\/jats:italic>\n                    54%, p&lt;0,001). A TT (0%\n                    <jats:italic>vs.<\/jats:italic>\n                    3%),\n                    illetve QT (0%\n                    <jats:italic>vs.<\/jats:italic>\n                    2%) c\u00e9ld\u00f3zis\u00fa alkalmaz\u00e1s\u00e1ban nem volt\n                    (p&gt;0,05) k\u00fcl\u00f6nbs\u00e9g a csoportok k\u00f6z\u00f6tt. A QT-t kap\u00f3k 1 \u00e9ves hal\u00e1loz\u00e1sa\n                    kedvez\u0151bben alakult (12%\n                    <jats:italic>vs.<\/jats:italic>\n                    13%\n                    <jats:italic>vs.<\/jats:italic>\n                    32%,\n                    p&lt;0,001; QT\n                    <jats:italic>vs.<\/jats:italic>\n                    TT\n                    <jats:italic>vs.<\/jats:italic>\n                    TT\/QT alkalmaz\u00e1s\u00e1nak\n                    hi\u00e1nya).\n                    <jats:italic>K\u00f6vetkeztet\u00e9sek:<\/jats:italic>\n                    Az ESC 2021-es Sz\u00edvel\u00e9gtelens\u00e9g\n                    Ir\u00e1nyelve \u00e1tt\u00f6r\u00e9st hozott a cs\u00f6kkent ejekci\u00f3s frakci\u00f3j\u00fa sz\u00edvel\u00e9gtelens\u00e9g\n                    gy\u00f3gyszeres kezel\u00e9s\u00e9ben. Eredm\u00e9nyeink bizony\u00edtj\u00e1k, hogy az SGLT2i-k bevezet\u00e9se,\n                    a QT alkalmaz\u00e1sa a hazai gyakorlatban is megval\u00f3s\u00edthat\u00f3 a sz\u00edvel\u00e9gtelens\u00e9g miatt\n                    hospitaliz\u00e1lt betegekn\u00e9l, melyek mellett kedvez\u0151bb progn\u00f3zis figyelhet\u0151 meg,\n                    mint a TT-t\/QT-t nem kap\u00f3 betegekn\u00e9l. Orv Hetil. 2024; 165(18): 698\u2013710.\n                  <\/jats:p>","DOI":"10.1556\/650.2024.33045","type":"journal-article","created":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T04:48:37Z","timestamp":1714970917000},"page":"698-710","update-policy":"https:\/\/doi.org\/10.1556\/policypage.crossmark.crossref.2","source":"Crossref","is-referenced-by-count":13,"title":["A cs\u00f6kkent ejekci\u00f3s frakci\u00f3j\u00fa sz\u00edvel\u00e9gtelens\u00e9g gy\u00f3gyszeres kezel\u00e9s\u00e9nek v\u00e1ltoz\u00e1sa \u00e9s a progn\u00f3zisra gyakorolt hat\u00e1sa a hazai gyakorlatban"],"prefix":"10.1556","volume":"165","author":[{"given":"Bal\u00e1zs","family":"Muk","sequence":"first","affiliation":[{"name":"Gottsegen Gy\u00f6rgy Orsz\u00e1gos Kardiovaszkul\u00e1ris Int\u00e9zet, Feln\u0151tt Kardiol\u00f3giai Oszt\u00e1ly Budapest, Haller u. 29., 1096 Magyarorsz\u00e1g"},{"name":"Szegedi Tudom\u00e1nyegyetem, Szent-Gy\u00f6rgyi Albert Orvostudom\u00e1nyi Kar, Klinikai Orvostudom\u00e1nyi Doktori Iskola Szeged Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D\u00e1vid","family":"Pilecky","sequence":"additional","affiliation":[{"name":"Gottsegen Gy\u00f6rgy Orsz\u00e1gos Kardiovaszkul\u00e1ris Int\u00e9zet, Feln\u0151tt Kardiol\u00f3giai Oszt\u00e1ly Budapest, Haller u. 29., 1096 Magyarorsz\u00e1g"},{"name":"Szegedi Tudom\u00e1nyegyetem, Szent-Gy\u00f6rgyi Albert Orvostudom\u00e1nyi Kar, Klinikai Orvostudom\u00e1nyi Doktori Iskola Szeged Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanni","family":"B\u00e1nfi-Bacs\u00e1rdi","sequence":"additional","affiliation":[{"name":"Gottsegen Gy\u00f6rgy Orsz\u00e1gos Kardiovaszkul\u00e1ris Int\u00e9zet, Feln\u0151tt Kardiol\u00f3giai Oszt\u00e1ly Budapest, Haller u. 29., 1096 Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tam\u00e1s","family":"F\u00fczesi","sequence":"additional","affiliation":[{"name":"Gottsegen Gy\u00f6rgy Orsz\u00e1gos Kardiovaszkul\u00e1ris Int\u00e9zet, Feln\u0151tt Kardiol\u00f3giai Oszt\u00e1ly Budapest, Haller u. 29., 1096 Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. Tam\u00e1s","family":"Gergely","sequence":"additional","affiliation":[{"name":"Gottsegen Gy\u00f6rgy Orsz\u00e1gos Kardiovaszkul\u00e1ris Int\u00e9zet, Feln\u0151tt Kardiol\u00f3giai Oszt\u00e1ly Budapest, Haller u. 29., 1096 Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Kom\u00e1romi","sequence":"additional","affiliation":[{"name":"Gottsegen Gy\u00f6rgy Orsz\u00e1gos Kardiovaszkul\u00e1ris Int\u00e9zet, Feln\u0151tt Kardiol\u00f3giai Oszt\u00e1ly Budapest, Haller u. 29., 1096 Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emese","family":"Papp","sequence":"additional","affiliation":[{"name":"Gottsegen Gy\u00f6rgy Orsz\u00e1gos Kardiovaszkul\u00e1ris Int\u00e9zet, Feln\u0151tt Kardiol\u00f3giai Oszt\u00e1ly Budapest, Haller u. 29., 1096 Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mih\u00e1ly D\u00e1niel","family":"Sz\u0151nyi","sequence":"additional","affiliation":[{"name":"Gottsegen Gy\u00f6rgy Orsz\u00e1gos Kardiovaszkul\u00e1ris Int\u00e9zet, Feln\u0151tt Kardiol\u00f3giai Oszt\u00e1ly Budapest, Haller u. 29., 1096 Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zsolt","family":"Forrai","sequence":"additional","affiliation":[{"name":"Gottsegen Gy\u00f6rgy Orsz\u00e1gos Kardiovaszkul\u00e1ris Int\u00e9zet, Feln\u0151tt Kardiol\u00f3giai Oszt\u00e1ly Budapest, Haller u. 29., 1096 Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1d\u00e1m","family":"Kazay","sequence":"additional","affiliation":[{"name":"Gottsegen Gy\u00f6rgy Orsz\u00e1gos Kardiovaszkul\u00e1ris Int\u00e9zet, Feln\u0151tt Kardiol\u00f3giai Oszt\u00e1ly Budapest, Haller u. 29., 1096 Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bal\u00e1zs","family":"Solymossi","sequence":"additional","affiliation":[{"name":"Gottsegen Gy\u00f6rgy Orsz\u00e1gos Kardiovaszkul\u00e1ris Int\u00e9zet, Feln\u0151tt Kardiol\u00f3giai Oszt\u00e1ly Budapest, Haller u. 29., 1096 Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e1t\u00e9","family":"V\u00e1mos","sequence":"additional","affiliation":[{"name":"Szegedi Tudom\u00e1nyegyetem, Szent-Gy\u00f6rgyi Albert Orvostudom\u00e1nyi Kar, Klinikai Orvostudom\u00e1nyi Doktori Iskola Szeged Magyarorsz\u00e1g"},{"name":"Szegedi Tudom\u00e1nyegyetem, Szent-Gy\u00f6rgyi Albert Orvostudom\u00e1nyi Kar, Belgy\u00f3gy\u00e1szati Klinika, Kardiol\u00f3giai Centrum, Elektrofiziol\u00f3giai R\u00e9szleg Szeged Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e9ter","family":"Andr\u00e9ka","sequence":"additional","affiliation":[{"name":"Gottsegen Gy\u00f6rgy Orsz\u00e1gos Kardiovaszkul\u00e1ris Int\u00e9zet, Feln\u0151tt Kardiol\u00f3giai Oszt\u00e1ly Budapest, Haller u. 29., 1096 Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zsolt","family":"Pir\u00f3th","sequence":"additional","affiliation":[{"name":"Gottsegen Gy\u00f6rgy Orsz\u00e1gos Kardiovaszkul\u00e1ris Int\u00e9zet, Feln\u0151tt Kardiol\u00f3giai Oszt\u00e1ly Budapest, Haller u. 29., 1096 Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"No\u00e9mi","family":"Nyolczas","sequence":"additional","affiliation":[{"name":"Gottsegen Gy\u00f6rgy Orsz\u00e1gos Kardiovaszkul\u00e1ris Int\u00e9zet, Feln\u0151tt Kardiol\u00f3giai Oszt\u00e1ly Budapest, Haller u. 29., 1096 Magyarorsz\u00e1g"},{"name":"Szegedi Tudom\u00e1nyegyetem, Szent-Gy\u00f6rgyi Albert Orvostudom\u00e1nyi Kar, Klinikai Orvostudom\u00e1nyi Doktori Iskola Szeged Magyarorsz\u00e1g"},{"name":"\u00c9szak-Pesti Centrumk\u00f3rh\u00e1z \u2013 Honv\u00e9dk\u00f3rh\u00e1z, Kardiol\u00f3giai Oszt\u00e1ly Budapest Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"425","reference":[{"key":"R1","doi-asserted-by":"crossref","unstructured":"Groenewegen A, Rutten FH, Mosterd A, et al. Epidemiology of heart\n                    failure. Eur J Heart Fail. 2020; 22: 1342\u20131356.","DOI":"10.1002\/ejhf.1858"},{"key":"R2","doi-asserted-by":"crossref","unstructured":"Ponikowski P, Anker SD, AlHabib KF, et al. Heart failure: preventing\n                    disease and death worldwide. ESC Heart Fail. 2014; 1: 4\u201325.","DOI":"10.1002\/ehf2.12005"},{"key":"R3","doi-asserted-by":"crossref","unstructured":"Savarese G, Becher PM, Lund LH, et al. Global burden of heart\n                    failure: a comprehensive and updated review of epidemiology. Cardiovasc Res.\n                    2023; 118: 3272\u20133287. Erratum: Cardiovasc Res. 2023; 119: 1453.","DOI":"10.1093\/cvr\/cvac013"},{"key":"R4","doi-asserted-by":"crossref","unstructured":"Tomcs\u00e1nyi J. Mortality among heart failure patient population in\n                    Hungary in 2017. [Sz\u00edvel\u00e9gtelens\u00e9gben szenved\u0151 betegek hal\u00e1loz\u00e1sa haz\u00e1nkban\n                    2017-ben.] Orv Hetil. 2020; 161: 1012\u20131014. [Hungarian]","DOI":"10.1556\/650.2020.31748"},{"key":"R5","doi-asserted-by":"crossref","unstructured":"Mamas MA, Sperrin M, Watson MC, et al. Do patients have worse\n                    outcomes in heart failure than in cancer? A primary care-based cohort study with\n                    10-year follow-up in Scotland. Eur J Heart Fail. 2017; 19:\n                    1095\u20131104.","DOI":"10.1002\/ejhf.822"},{"key":"R6","doi-asserted-by":"crossref","unstructured":"Lloyd-Jones DM, Larson MG, Leip EP, et al. Lifetime risk for\n                    developing congestive heart failure: the Framingham heart study. Circulation\n                    2002; 106: 3068\u20133072.","DOI":"10.1161\/01.CIR.0000039105.49749.6F"},{"key":"R7","unstructured":"Tomcs\u00e1nyi J, Toth E. Epidemiology and therapy of heart failure in\n                    the early XXI. century. [Sz\u00edvel\u00e9gtelens\u00e9g epidemiol\u00f3gi\u00e1ja \u00e9s ter\u00e1pi\u00e1ja\n                    Magyarorsz\u00e1gon a XXI. sz\u00e1zad elej\u00e9n.] Cardiol Hung. 2012; 42: 155\u2013162.\n                    [Hungarian]"},{"key":"R8","doi-asserted-by":"crossref","unstructured":"McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin\n                    inhibition versus enalapril in heart failure. N Engl J Med. 2014; 371:\n                    993\u20131004.","DOI":"10.1056\/NEJMoa1409077"},{"key":"R9","doi-asserted-by":"crossref","unstructured":"Packer M, Anker SD, Butler J, et al. Cardiovascular and renal\n                    outcomes with empagliflozin in heart failure. N Engl J Med. 2020; 383:\n                    1413\u20131424.","DOI":"10.1056\/NEJMoa2022190"},{"key":"R10","doi-asserted-by":"crossref","unstructured":"McMurray JJ, Solomon SD, Inzucchi SE, et al. Dapagliflozin in\n                    patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;\n                    381: 1995\u20132008.","DOI":"10.1056\/NEJMoa1911303"},{"key":"R11","doi-asserted-by":"crossref","unstructured":"Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the\n                    diagnosis and treatment of acute and chronic heart failure: the Task Force for\n                    the diagnosis and treatment of acute and chronic heart failure of the European\n                    Society of Cardiology (ESC). Developed with the special contribution of the\n                    Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016; 18:\n                    891\u2013975.","DOI":"10.1093\/eurheartj\/ehw128"},{"key":"R12","doi-asserted-by":"crossref","unstructured":"McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the\n                    diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;\n                    42: 3599\u20133726. Erratum: Eur Heart J. 2021; 42: 4901.","DOI":"10.1093\/eurheartj\/ehab670"},{"key":"R13","unstructured":"Muk B. Practical implementation of the 2021 European Society of\n                    Cardiology Heart Failure Guidelines \u2013 focusing on the Guideline-directed medical\n                    therapy for heart failure with reduced ejection fraction. [Fo\u0301kuszban a\n                    cso\u0308kkent ejekcio\u0301s frakcio\u0301ju\u0301 szi\u0301vele\u0301gtelense\u0301g gyo\u0301gyszeres kezele\u0301se.]\n                    Cardiol Hung. 2023; 53: 351\u2013359. [Hungarian]"},{"key":"R14","doi-asserted-by":"crossref","unstructured":"Kov\u00e1cs \u00c1. The new slogen in the baseline pharmacological therapy of\n                    heart failure with reduced ejection fraction: ASAP! [Az u\u0301j jelszo\u0301 a cso\u0308kkent\n                    ejekcio\u0301s frakcio\u0301val ja\u0301ro\u0301 szi\u0301vele\u0301gtelense\u0301g ba\u0301zistera\u0301pia\u0301ja\u0301ban: ASAP!]\n                    Cardiol Hung. 2023; 53: 502\u2013506. [Hungarian]","DOI":"10.26430\/CHUNGARICA.2023.53.5.502"},{"key":"R15","doi-asserted-by":"crossref","unstructured":"Voith L, \u00c9des IF, Skoda R, et al. Non-ST-elevation infarction, the\n                    stepchild of interventional myocardial salvage: experience of a single\n                    institute. [Nem ST-elev\u00e1ci\u00f3s infarktus \u2013 az intervenci\u00f3s sz\u00edvizomment\u00e9s\n                    mostohagyereke. Egy int\u00e9zet tapasztalatai.] Orv Hetil. 2023; 164: 1865\u20131870.\n                    [Hungarian]","DOI":"10.1556\/650.2023.32862"},{"key":"R16","doi-asserted-by":"crossref","unstructured":"K\u00f6r\u00f6mi Z, Nagy GG. Influenza as a threat to cardiovascular health\n                    and the role of vaccination in risk reduction. [Az influenza mint kardiol\u00f3giai\n                    rizik\u00f3t\u00e9nyez\u0151 \u00e9s a vakcin\u00e1ci\u00f3 szerepe a kock\u00e1zat cs\u00f6kkent\u00e9s\u00e9ben.] Orv Hetil.\n                    2022; 163: 1585\u20131596. [Hungarian]","DOI":"10.1556\/650.2022.32597"},{"key":"R17","doi-asserted-by":"crossref","unstructured":"Crespo-Leiro MG, Anker SD, Maggioni AP, et al. European Society of\n                    Cardiology Heart Failure Long-Term Registry (ESC-HF-LT): 1-year follow-up\n                    outcomes and differences across regions. Eur J Heart Fail. 2016; 18: 613\u2013625.\n                    Erratum: Eur J Heart Fail. 2017; 19: 438.","DOI":"10.1002\/ejhf.566"},{"key":"R18","doi-asserted-by":"crossref","unstructured":"Nyolczas N, Heltai K, Borb\u00e9ly A, et al. Hungarian Heart Failure\n                    Registry 2015\u20132016. Preliminary results. [Magyar Sz\u00edvel\u00e9gtelens\u00e9g Regiszter\n                    2015\u20132016. Kezdeti eredm\u00e9nyek.] Orv Hetil. 2017; 158: 94\u2013100.\n                    [Hungarian]","DOI":"10.1556\/650.2017.30671"},{"key":"R19","unstructured":"Protocol for diagnosis and therapy of chronic adult kidney disease.\n                    Ministry of Human Resources. [Az Emberi Ero\u030bforra\u0301sok Miniszte\u0301riuma\n                    ege\u0301szse\u0301gu\u0308gyi szakmai ira\u0301nyelve a felno\u030bttkori idu\u0308lt vesebetegse\u0301g\n                    diagno\u0301zisa\u0301ro\u0301l e\u0301s kezele\u0301se\u0301ro\u030bl.] E\u00fc K\u00f6zl. 2021; 71: 1761\u20131826.\n                    [Hungarian]"},{"key":"R20","doi-asserted-by":"crossref","unstructured":"Zempl\u00e9nyi A, S\u00e1ghy E, K\u00f3nyi A, et al. Prevalence, cardiometabolic\n                    comorbidities and reporting of chronic kidney disease; a Hungarian cohort\n                    analysis. Int J Public Health 2023; 68: 1605635.","DOI":"10.3389\/ijph.2023.1605635"},{"key":"R21","doi-asserted-by":"crossref","unstructured":"Tomcs\u00e1nyi J, Ar\u00e1nyi P, K\u00e1ntor Z, et al. Chronic renal failure in\n                    patients hospitalized for heart failure. [Kr\u00f3nikus veseel\u00e9gtelens\u00e9g\n                    sz\u00edvel\u00e9gtelens\u00e9g miatt hospitaliz\u00e1lt betegekn\u00e9l.] Cardiol Hung. 2024; 54: 24\u201326.\n                    [Hungarian]","DOI":"10.26430\/CHUNGARICA.2024.54.1.24"},{"key":"R22","doi-asserted-by":"crossref","unstructured":"Boorsma EM, Ter Maaten JM, Damman K, et al. Albuminuria as a marker\n                    of systemic congestion in patients with heart failure. Eur Heart J. 2023; 44:\n                    368\u2013380.","DOI":"10.1093\/eurheartj\/ehac528"},{"key":"R23","doi-asserted-by":"crossref","unstructured":"Khan MS, Shahid I, Anker SD, et al. Albuminuria and heart failure:\n                    JACC state-of-the-art review. J Am Coll Cardiol. 2023; 81:\n                    270\u2013282.","DOI":"10.1016\/j.jacc.2022.10.028"},{"key":"R24","doi-asserted-by":"crossref","unstructured":"B\u00e1nfi-Bacs\u00e1rdi F, V\u00e1mos M, Majoros Z, et al. The effect of kidney\n                    function on the optimization of medical therapy and on mortality in heart\n                    failure with reduced ejection fraction. [A vesefunkci\u00f3 hat\u00e1sa a gy\u00f3gyszeres\n                    ter\u00e1pia optimaliz\u00e1l\u00e1s\u00e1ra \u00e9s a mortalit\u00e1sra cs\u00f6kkent ejekci\u00f3s frakci\u00f3j\u00fa\n                    sz\u00edvel\u00e9gtelens\u00e9gben.] Orv Hetil. 2023; 164: 1387\u20131396.\n                    [Hungarian]","DOI":"10.1556\/650.2023.32836"},{"key":"R25","doi-asserted-by":"crossref","unstructured":"Janse RJ, Fu EL, Dahlstr\u00f6m U, et al. Use of guideline-recommended\n                    medical therapy in patients with heart failure and chronic kidney disease: from\n                    physician\u2019s prescriptions to patient\u2019s dispensations, medication adherence and\n                    persistence. Eur J Heart Fail. 2022; 24: 2185\u20132195.","DOI":"10.1002\/ejhf.2620"},{"key":"R26","doi-asserted-by":"crossref","unstructured":"Patel RB, Fonarow GC, Greene SJ, et al. Kidney function and outcomes\n                    in patients hospitalized with heart failure. J Am Coll Cardiol. 2021; 78:\n                    330\u2013343.","DOI":"10.1016\/j.jacc.2021.05.002"},{"key":"R27","doi-asserted-by":"crossref","unstructured":"Cobo Marcos M, de la Espriella R, Gay\u00e1n Ord\u00e1s J, et al. Prevalence\n                    and clinical profile of kidney disease in patients with chronic heart failure.\n                    Insights from the Spanish cardiorenal registry. Rev Esp Cardiol (Engl ed) 2024;\n                    77: 50\u201359.","DOI":"10.1016\/j.rec.2023.05.003"},{"key":"R28","doi-asserted-by":"crossref","unstructured":"B\u00e1nfi-Bacs\u00e1rdi F, Pilecky D, V\u00e1mos M, et al. The effect of kidney\n                    function on guideline-directed medical therapy implementation and prognosis in\n                    heart failure with reduced ejection fraction. Clin Cardiol. 2024; 47:\n                    e24244.","DOI":"10.1002\/clc.24244"},{"key":"R29","doi-asserted-by":"crossref","unstructured":"Armstrong PW, Pieske B, Anstrom KJ, et al. Vericiguat in patients\n                    with heart failure and reduced ejection fraction. N Engl J Med. 2020; 382:\n                    1883\u20131893.","DOI":"10.1056\/NEJMoa1915928"},{"key":"R30","doi-asserted-by":"crossref","unstructured":"Teerlink JR, Diaz R, Felker GM, et al. Cardiac myosin activation\n                    with omecamtiv mecarbil in systolic heart failure. N Engl J Med. 2021; 384:\n                    105\u2013116.","DOI":"10.1056\/NEJMc2102893"},{"key":"R31","doi-asserted-by":"crossref","unstructured":"Greene SJ, Ezekowitz JA, Anstrom KJ, et al. Medical therapy during\n                    hospitalization for heart failure with reduced ejection fraction: the VICTORIA\n                    Registry. J Card Fail. 2022; 28: 1063\u20131077.","DOI":"10.1016\/j.cardfail.2022.02.011"},{"key":"R32","doi-asserted-by":"crossref","unstructured":"Greene SJ, Butler J, Albert NM, et al. Medical therapy for heart\n                    failure with reduced ejection fraction: the CHAMP-HF Registry. J Am Coll\n                    Cardiol. 2018; 72: 351\u2013366.","DOI":"10.1016\/j.jacc.2018.04.070"},{"key":"R33","doi-asserted-by":"crossref","unstructured":"Banfi-Bacs\u00e1rdi F, Muk B, Pilecky D, et al. Optimization of\n                    guideline-directed medical therapy during hospitalization among patients with\n                    heart failure with reduced ejection fraction in daily clinical practice.\n                    Cardiology 2023; 148: 27\u201337.","DOI":"10.1159\/000528505"},{"key":"R34","doi-asserted-by":"crossref","unstructured":"Thorvaldsen T, Ferrannini G, Mellbin L, et al. Eligibility for\n                    dapagliflozin and empagliflozin in a real-world heart failure population. J Card\n                    Fail. 2022; 28: 1050\u20131062.","DOI":"10.1016\/j.cardfail.2022.04.011"},{"key":"R35","doi-asserted-by":"crossref","unstructured":"Angelini G, Albanese M, Ursi R, et al. Eligibility of outpatients\n                    with chronic heart failure for sodium-glucose co-transporter-2 inhibitors. ESC\n                    Heart Fail. 2021; 8: 2951\u20132958.","DOI":"10.1002\/ehf2.13380"},{"key":"R36","doi-asserted-by":"crossref","unstructured":"Savarese G, Kishi T, Vardeny O, et al. Heart failure drug\n                    treatment-inertia, titration, and discontinuation: a multinational observational\n                    study (EVOLUTION HF). JACC Heart Fail. 2023; 11: 1\u201314. Erratum: JACC Heart Fail.\n                    2023; 11: 1773.","DOI":"10.1016\/j.jchf.2022.08.009"},{"key":"R37","doi-asserted-by":"crossref","unstructured":"D\u2019Amario D, Rodolico D, Delvinioti A, et al. Eligibility for the 4\n                    pharmacological pillars in heart failure with reduced ejection fraction at\n                    discharge. J Am Heart Assoc. 2023; 12: e029071.","DOI":"10.1161\/JAHA.122.029071"},{"key":"R38","doi-asserted-by":"crossref","unstructured":"Banfi-Bacsardi F, Muk B, Majoros ZS, et al. The effect of long-term\n                    application of guideline \u2013 directed medical therapy on systolic blood pressure\n                    in hospitalized patients with heart failure with reduced ejection fraction. Eur\n                    Heart J. 2023; 44(Suppl 2): ehad655.991.","DOI":"10.1093\/eurheartj\/ehad655.991"},{"key":"R39","doi-asserted-by":"crossref","unstructured":"McDonagh TA, Blue L, Clark AL, et al. European Society of Cardiology\n                    Heart Failure Association Standards for delivering heart failure care. Eur J\n                    Heart Fail. 2011; 13: 235\u2013241.","DOI":"10.1093\/eurjhf\/hfq221"},{"key":"R40","doi-asserted-by":"crossref","unstructured":"Muk B, B\u00e1nfi-Bacs\u00e1rdi F, V\u00e1mos M, et al. The impact of specialised\n                    heart failure outpatient care on the long-term application of guideline-directed\n                    medical therapy and on prognosis in heart failure with reduced ejection\n                    fraction. Diagnostics 2024; 14: 131.","DOI":"10.3390\/diagnostics14020131"},{"key":"R41","doi-asserted-by":"crossref","unstructured":"Mebazaa A, Davison B, Chioncel O, et al. Safety, tolerability and\n                    efficacy of up-titration of guideline-directed medical therapies for acute heart\n                    failure (STRONG-HF): a multinational, open-label, randomised, trial. Lancet\n                    2022; 400: 1938\u20131952.","DOI":"10.1016\/S0140-6736(22)02076-1"},{"key":"R42","doi-asserted-by":"crossref","unstructured":"McDonagh TA, Metra M, Adamo M, et al. 2023 Focused update of the\n                    2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart\n                    failure. Eur Heart J. 2023; 44: 3627\u20133639. Erratum: Eur Heart J. 2024; 45:\n                    53.","DOI":"10.1093\/eurheartj\/ehad613"},{"key":"R43","doi-asserted-by":"crossref","unstructured":"Tromp J, Ouwerkerk W, van Veldhuisen DJ, et al. A systematic review\n                    and network meta-analysis of pharmacological treatment of heart failure with\n                    reduced ejection fraction. JACC Heart Fail. 2022; 10: 73\u201384.","DOI":"10.1016\/j.jchf.2021.09.004"},{"key":"R44","doi-asserted-by":"crossref","unstructured":"Vaduganathan M, Claggett BL, Jhund PS, et al. Estimating lifetime\n                    benefits of comprehensive disease-modifying pharmacological therapies in\n                    patients with heart failure with reduced ejection fraction: a comparative\n                    analysis of three randomised controlled trials. Lancet 2020; 396:\n                    121\u2013128.","DOI":"10.1016\/S0140-6736(20)30748-0"},{"key":"R45","doi-asserted-by":"crossref","unstructured":"Breathett K, Allen LA, Udelson J, et al. Changes in left ventricular\n                    ejection fraction predict survival and hospitalization in heart failure with\n                    reduced ejection fraction. Circ Heart Fail. 2016; 9: e002962.","DOI":"10.1161\/CIRCHEARTFAILURE.115.002962"},{"key":"R46","doi-asserted-by":"crossref","unstructured":"Couissi A, Haboub M, Hamady S, et al. Predictors of mortality in\n                    heart failure patients with reduced or mildly reduced ejection fraction: the\n                    CASABLANCA HF Study. Egypt Heart J. 2024; 76: 5.","DOI":"10.1186\/s43044-024-00436-y"},{"key":"R47","doi-asserted-by":"crossref","unstructured":"Khan MS, Butler J, Greene SJ. The real world of de novo heart\n                    failure: the next frontier for heart failure clinical trials? Eur J Heart Fail.\n                    2020; 22: 1786\u20131789.","DOI":"10.1002\/ejhf.1844"}],"container-title":["Orvosi Hetilap"],"original-title":[],"link":[{"URL":"https:\/\/www.akjournals.com\/view\/journals\/650\/165\/18\/article-p698.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.akjournals.com\/downloadpdf\/journals\/650\/165\/18\/article-p698.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/www.akjournals.com\/downloadpdf\/journals\/650\/165\/18\/article-p698.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T14:05:10Z","timestamp":1784815510000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.akjournals.com\/view\/journals\/650\/165\/18\/article-p698.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,5]]},"references-count":47,"journal-issue":{"issue":"18"},"URL":"https:\/\/doi.org\/10.1556\/650.2024.33045","relation":{},"ISSN":["0030-6002","1788-6120"],"issn-type":[{"value":"0030-6002","type":"print"},{"value":"1788-6120","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,5]]}}}